Are We Closing In on a Breakthrough in Autism Treatment?

Autism has proven to be one of the most difficult-to-treat indications, but troublesome symptoms may someday find new relief. Last week, Roche Holdings (NASDAQOTH:RHHBY) announced it had received breakthrough therapy status from the Food and Drug Administration for balovaptan, a potential therapy for autism spectrum disorder.

If future trials confirm balovaptan’s promise, it could

Read the full article at the original source

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.